Praziquantel
Active ingredient: Praziquantel
In short: Praziquantel tablets are indicated in patients aged 1 year and older for the treatment of the following infections: Schistosomiasis due to all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and Clonorchiasis and Opist
What is Praziquantel used for?
Praziquantel tablets are indicated in patients aged 1 year and older for the treatment of the following infections:
Schistosomiasis due to all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium), and
Clonorchiasis and Opisthorchiasis due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated)
Praziquantel dosage
Schistosomiasis The recommended dosage for the treatment of schistosomiasis is 20 mg/kg bodyweight administered orally three times a day separated by 4 to 6 hours, for 1 day only.
Clonorchiasis and Opisthorchiasis
The recommended dosage for the treatment of clonorchiasis and opisthorchiasis is 25 mg/kg bodyweight administered orally three times a day separated by 4 to 6 hours for 1 day only.
Take tablets with water during meals. Do not chew or keep the tablets (or parts of tablets) in the mouth; the bitter taste may cause gagging or vomiting. To prevent choking in pediatric patients under 6 years of age, the tablets may be crushed or disintegrated and mixed with semi-solid food or liquid. Use crushed or disintegrated tablets within 1 hour of mixing.
Praziquantel 600 mg tablets have three scores which can be split into four segments at the scores. When broken, each of the four segments contains 150 mg of praziquantel so that the dosage can be adjusted to the patient’s bodyweight. Segments are broken off by pressing the score (notch) with thumbnails. If one-quarter of a tablet is required, this is best achieved by breaking the segment from the outer end.
How to take Praziquantel — instructions & advice from the label
Advise patients to take praziquantel during meals as directed .
Advise patients not to chew tablets and to take them with water
Advise patients that tablets may be crushed or disintegrated and mixed with semi-solid food or liquid or disintegrated to prevent choking in children under 6 years of age. Crushed or disintegrated tablets should be used within 1 hour of mixing .
Advise patients not to take praziquantel tablets if they are allergic to praziquantel or any of its components .
Advise patients not to take praziquantel if they are taking rifampin
.
Advise patients not to take praziquantel if they are taking efavirenz .
Advise patients that the use of praziquantel can be associated with clinical deterioration during the acute phase of schistosomiasis .
Advise patients that praziquantel should not be used if they have epilepsy or other CNS effects .
Advise patients to report any cardiac irregularities to their healthcare provider .
Advise patients not to drive a car and not to operate machinery on the day of praziquantel treatment and the following day.
Manufactured for:
Par Health USA
Woodcliff Lake, NJ 07677 U.S.A. …
Warnings & precautions
Do not take this medicine if: Praziquantel is contraindicated in:
Patients who previously have shown hypersensitivity to praziquantel or any of the excipients in praziquantel tablets.
Patients with ocular cysticercosis; since parasite destruction within the eye that occurs because of hypersensitivity reaction to the dead parasite after treatment may cause irreversible lesions, ocular cysticercosis must not be treated with praziquantel.
Patients taking strong Cytochrome P450 3A enzyme (CYP 3A) inducers, such as rifampin [see
Warnings
and
Precautions
(
5.6)
and
Drug
Interactions (
7.1
,
7.2)].
The use of praziquantel in patients with schistosomiasis may be associated with clinical deterioration (for example, paradoxical reactions, serum sickness Jarisch-Herxheimer like reactions: sudden inflammatory immune response suspected to be caused by the release of schistosomal antigens). These reactions predominantly occur in patients treated during the acute phase of schistosomiasis. They may lead to potentially life-threatening events, for example, respiratory failure, encephalopathy, papilledema, and/or cerebral vasculitis.
Praziquantel can exacerbate central nervous system pathology due to schistosomiasis, paragonimiasis, or Taenia solium cysticercosis. As a general rule, consider whether to administer praziquantel to individuals reporting a history of epilepsy and/or other signs of potential central nervous systems involvement such as subcutaneous nodules suggestive of cysticercosis unless the potential benefit justifies the potential risk. Hospitalize the patient for duration of treatment when schistosomiasis or fluke infection is found to be associated with cerebral cysticercosis. …
Praziquantel side effects
The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling:
Clinical Deterioration
Central Nervous System (CNS) Effects
Potential Lack of Efficacy During the Acute Phase of Schistosomiasis
Cardiac Arrhythmias
Hepatic Impairment in Hepatosplenic Schistosomiasis Patients
Concomitant Administration with Strong Cytochrome P450 Inducers
The following adverse reactions associated with the use of praziquantel were identified in clinical studies, published literature or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions were observed in both adults and pediatric patients:
General disorders and administration site conditions: malaise, pyrexia
Nervous system disorders: headache, dizziness
Gastrointestinal disorders: abdominal discomfort, nausea
Skin and subcutaneous tissue disorders: urticaria
Such adverse reactions may be more frequent and/or serious in patients with a heavy worm burden. …
Drug interactions
Strong and Moderate CYP 3A Inducers
Concomitant administration of praziquantel with Strong and Moderate CYP 3A inducers decrease praziquantel AUC and Cmax
which may reduce the efficacy of praziquantel. Concomitant administration of a Strong CYP 3A inducer, such as rifampin, with praziquantel is contraindicated . Concomitant administration of a Moderate CYP 3A inducer, such as efavirenz, should be avoided unless the benefit outweighs the risks
Concomitant administration of drugs that decrease the activity of drug metabolizing liver enzymes (CYP450 inhibitors), for example, cimetidine, ketoconazole, itraconazole, erythromycin, and ritonavir may increase plasma concentrations of praziquantel. In addition, grapefruit juice was also reported to produce a 1.6-fold increase in the Cmax and a 1.9-fold increase in the AUC of praziquantel. The effect of this exposure increase on the safety of praziquantel has not been systematically evaluated .
About this medicine
Praziquantel, USP is an anthelmintic, trematodicide provided in tablet form for oral administration.
Praziquantel, USP is 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a] isoquinolin-4-one with the molecular formula; C19H24N2O2. The structural formula is as follows:
Praziquantel, USP is a white or almost white crystalline powder. The compound is stable under normal conditions and melts at 136°C to 142°C. The active substance is non-hygroscopic. Praziquantel, USP is freely soluble in ethanol (96 per cent) and in methylene chloride, practically insoluble in water.
Praziquantel tablets, USP contain 600 mg of praziquantel, USP. Inactive ingredients: corn starch, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, povidone, sodium lauryl sulfate, polyethylene glycol, titanium dioxide and hypromellose.
How it works: Praziquantel is an anthelmintic drug . Absorption After oral administration, 80% of an administered praziquantel dose is absorbed, with maximal serum concentrations of praziquantel achieved 1 to 3 hours after dosing. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 16f2b9c4-a260-4a31-bd52-e5945913246c. Read the full official label on DailyMed.